Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines for patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of severe and debilitating diseases.
Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi discovery platform and deep pipeline of investigational medicines including one approved medicine in Canada, the EU and Japan, and two approved medicines in the U.S., five programs in late-stage clinical development and multiple programs in early-stage clinical development.
RNAi: A REVOLUTION IN BIOLOGY BUILT ON NOBEL PRIZE-WINNING RESEARCH
RNA interference (RNAi) is a breakthrough in understanding how genes are regulated in cells. It also represents a completely new approach to drug discovery and development. The 2006 Nobel Prize for Physiology or Medicine, awarded to Craig Mello and Andrew Fire, recognized the importance of RNAi as a major scientific discovery.
Our pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need that fall into 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS) and ocular diseases.
JOIN OUR TEAM
JOIN OUR TEAM
We are growing quickly and hiring across North America, Europe, Asia, and Latin America for a wide variety of roles. We’re seeking smart, passionate, “change the world” kind of people who are ready to say, “challenge accepted” to our mission.